Businessweek

Verenium Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company has posted total revenues decreased 20% to $13.8 million from $17.2 million in the prior year, primarily due to license revenue recorded in 2012 from DSM and Novus International. Loss from operations was $3.8 million compared to income from operations of $32.0 million for the prior year, on a GAAP accounting basis, including the impact of the $31.3 million gain on sale of the oilseed processing business to DSM in 2012. Adjusted LBITDA was $2.5 million, compared to Adjusted EBITDA income of $1.4 million for the same quarter in the prior year. The change in Adjusted EBITDA is primarily attributed to license revenue recorded in 2012 from DSM and Novus International, and increased research and development expenses. Net loss from continuing operations was $6.05 million against net income from continuing operations of $29.31 million a year ago. Net loss attributed to Verenium was $6.05 million or $0.47 diluted per share against net income of $29,301,000 or $2.32 diluted per share a year ago. For the year 2013, the company expects adjusted LBITDA to be in between $10 million to $12 million and capital expenditures to be in between $3 million to $4 million.

Verenium Corporation, Q1 2013 Earnings Call, May 09, 2013

Verenium Corporation announced that they will report Q1, 2013 results After-Market on May 09, 2013

Verenium Corporation reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2012. For the quarter, the company's total revenue was $13.98 million compared with $14.3 million a year ago. Loss from operations was $3.2 million compared with $2.6 million a year ago. Net loss from continuing operations before income taxes was $3.99 million compared with $3.1 million a year ago. Net loss from continuing operations was $3.6 million or $0.28 per basic share compared with $2.7 million or $0.22 per basic share a year ago. Net loss attributed to the company was $3.6 million or $0.28 per basic share compared with $2.9 million or $0.23 per basic share a year ago. Non-GAAP pro forma loss from operations was $3.2 million compared with $2.6 million a year ago. Non-GAAP pro forma net loss from continuing operations was $4.0 million or $0.31 per basic share compared with $3.2 million or $0.26 per basic share a year ago. For the year, the company's total revenue was $57.2 million compared with $61.3 million a year ago. Income from operations was $21.7 million compared with loss from operations of $6.2 million a year ago. Net income from continuing operations before income taxes was $18.5 million compared with $5.3 million a year ago. Net income from continuing operations was $18.3 million or $1.44 per basic share compared with $5.6 million or $0.45 per basic share a year ago. Net income attributed to the company was $18.2 million or $1.43 per basic share compared with $5.5 million or $0.44 per basic share a year ago. Non-GAAP pro forma loss from operations was $9.6 million compared with $3.2 million a year ago. Non-GAAP pro forma net loss from continuing operations was $12.2 million or $0.96 per basic share compared with $6.3 million or $0.50 per basic share a year ago, primarily due to a decrease in product and contract manufacturing gross profit and continued research and development investment in pipeline products. The company expects to see revenue and gross profit growth over 2012. Operating expenses are expects to increase over 2012, primarily due to continued R&D investment in bringing existing pipeline products to market and adding new candidates to the pipeline. Capital expenditures expects to decrease in 2013 as investment in new facility and laboratory build-out is now complete, and the company focus 2013 capital investments on continued enhancements in manufacturing, with an eye toward decreasing manufacturing variability and bringing down cost of goods.

Verenium Corporation, Q4 2012 Earnings Call, Mar 27, 2013